Search Results for "Immunotherapy"

Initial treatment with two monoclonal antibodies significantly improves survival for patients with BRAF V600-variant advanced melanoma compared to treatment with two targeted agents, researchers reported during the November 2021 ASCO Plenary Series meeting. The initial findings were so conclusive that the study’s data safety and monitoring board stopped the trial early.

Patients with melanoma who consume a high-fiber diet during treatment with immune checkpoint inhibitors (ICIs) or anti-PD-1 therapy experience longer progression-free survival than those who don’t, researchers reported in Science. And probiotic supplementation, often considered a healthy behavior, reduces immunotherapy response.

If you’re a nurse who is new to oncology, administering or planning to administer chemotherapy/immunotherapy, or caring for patients receiving chemotherapy this course is your first stop.

This certificate course prepares and reinforces critical information for safe administration and use evidence to manage acute side effects and adverse events related to chemotherapy and immunotherapy administration. 

Using antibiotics during treatment with immune checkpoint inhibitors may limit the therapy’s effect, according to study results published in the American Journal of Clinical Oncology.

ONS member Theresa Latchford, RN, MS, AOCNS^®, BMTCN^®, clinical nurse specialist at Stanford Health Care in Palo Alto, CA, and member of the Silicon Valley ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss cytokine release syndrome and its associated immunotherapies. This episode is part of a new series about oncologic emergencies. We’ll add a link to future episodes in the show notes after the second episode next month.

Immune checkpoint inhibitors (ICIs) enhance immune response against foreign antigens, such as cancer, by manipulating checkpoints that have stopped the body from fighting them. In doing so, they also increase risk of the immune system attacking healthy cells and producing inflammatory side effects, resulting in immune-related adverse events (irAEs).

Immunotherapy has revolutionized cancer treatment, especially for patients with diseases considered otherwise incurable. Since May 2017, the U.S. Food and Drug Administration (FDA) has approved 27 immunotherapy combinations, including chemoimmunotherapy and regimens with targeted therapies, and researchers are reporting highly promising data from clinical trials of its combination with radiation.

Randi is a 57-year-old patient who identifies as female. She was diagnosed with clear cell metastatic renal cell carcinoma (mRCC), and her past medical history includes mild hypertension managed with amlodipine and a two-year history of transient musculoskeletal pain managed with tramadol. She reports a family history of cardiovascular disease and rheumatoid arthritis (RA). Her primary care physician suspects Randi is at the beginning stages of fibromyalgia but has not made a conclusive diagnosis because she hasn’t experienced additional symptoms.

Combination treatment with an oncolytic virus plus a PD-1 inhibitor shows promise in patients with nonmelanoma skin cancers, researchers reported in early study results during the 2022 Multidisciplinary Head and Neck Cancers Symposium.